In exclusive clinical partnership with KPCIRC
OnKommon

Precision Oncology, Navigated

Because every life deserves every option.

A diagnosis narrows your world to one question: what now? We turn the full molecular picture of your cancer into a clear, ranked plan, and put a clinical team beside you to act on it.

Not a test result. A decision, and someone to walk it with you.

02The problem

A variant list is not a decision

Genomic tests can read hundreds of genes. Most people get back a page of letters and numbers, and no answer to the questions that actually matter.

  • Which treatment gives me the best chance, first?
  • What should I not be given, and why?
  • Are there trials or lower-cost equivalent drugs?
  • If this stops working, how will we catch it early?

We do the hard part: turning data into a decision you can act on.

A dense raw sequencing printout on the left, and page one of an OnKommon Plan on the right showing an Actionability Index of 82 and a first-line recommendation.
Left: what most people are handed. Right: what we give back.

03The service

What OnKommon is

We bring together three things that are usually scattered: comprehensive molecular testing, expert interpretation, and continuous human care.

The intelligence

OnKommon builds the technology, the engine and the report.

The clinical authority

KPCIRC, our exclusive partner, signs every decision.

The two questions answered

A licensed clinician is accountable. No machine decides.

Our technology informs. A clinician decides.

04The ecosystem

One journey, four jobs

Most people start with Blueprint Care and grow into the rest as their needs change.

Stage 01

Decide

Blueprint Care

Read the whole tumour and rank the best treatment plan.

Blueprint Care

Stage 02

Track

Sentinel

Watch whether treatment is working and catch resistance early.

Sentinel

Stage 03

Catch

Clear

Detect microscopic disease left behind or coming back.

Clear

Stage 04

Protect

Heritage

Test for inherited risk and protect your family.

Heritage
Blueprint Care
DecideMake the right plan
Sentinel
TrackResponse and resistance
Clear
CatchMolecular residual disease
Heritage
ProtectInherited risk

Always connected. Navigation, clinical review, reporting and human guidance continue as needs change.

Phase 01

Understand what is driving the cancer.

Begin with the molecular picture and turn scattered information into a ranked, clinically accountable plan. The goal is not another variant list. It is a clear decision the treating team can act on.

  • Molecular profiling
  • Ranked treatment plan
  • Clinical sign-out

Select a stage to move through the journey. Each product bar shows when it is active.

05Three stages

How it works

Every report follows the same path. Each stage is traceable, and a licensed human owns the last word.

  1. SequenceAn accredited laboratory reads the DNA

    From a blood draw or a tissue block, with quality control and per-gene coverage reported openly.

  2. InterpretThe OnKommon engine analyses it

    It annotates every alteration, matches drugs and trials, and applies six intelligence layers.

  3. Sign outKPCIRC authors and signs the plan

    A molecular tumour board of licensed clinicians adds judgement and takes responsibility.

From the blood draw at home through to the signed plan.

06What is different

Why OnKommon

A decision, not a data dump

We rank the options, name what to avoid, and explain why.

Human authority by design

Licensed clinicians author every consequential call.

Built for India

Biosimilars, assistance programmes and government schemes, in your language.

One connected ecosystem

The same team follows you from first decision to long-term monitoring.

Radically transparent

We say what each test cannot do, and who signed your report.

Family included

Where inherited risk shows up, relatives get a tested pathway and counselling.

523genes on our widest blood panel
35pharmacogenomic genes in every test
6intelligence layers on every case
4 hrsto a free first answer on WhatsApp
Six clinicians around a table at KPCIRC discussing a case, with the molecular tumour board case summary on the screen behind them.
The KPCIRC molecular tumour board reviewing a case.

07Our origin

Born inside KPCIRC

OnKommon began inside the Kwatra Precision Cancer Institute and Research Centre, and stays in exclusive clinical partnership with it.

That is why our reports arrive with genuine clinical accountability rather than software output. It is the difference between a result and a plan.

Meet our clinical partner

08Start where you are

Find your door

By where you are

Take the next step

Three ways forward. Pick the one that fits today.

01

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation
02

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care
03

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal